872511-34-7 Usage
Description
3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-[6-[[4-(4-ethylpiperazin-1-yl)phenyl]amino]pyrimidin-4-yl]-1-methylurea, also known as NVP-BGJ398, is a potent and selective pan-FGFR inhibitor with IC50 values of 0.9nM, 1.4 nM, 1.0 nM, and 60 nM for FGFR1, 2, 3, and 4, respectively. It is a small molecule compound that has been used in research and therapeutic development, particularly for conditions related to the fibroblast growth factor receptor family of receptor tyrosine kinase.
Uses
Used in Pharmaceutical Industry:
3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-[6-[[4-(4-ethylpiperazin-1-yl)phenyl]amino]pyrimidin-4-yl]-1-methylurea is used as a therapeutic agent for the treatment of various cancers and diseases driven by the activation of FGFRs. Its potent and selective inhibition of the FGFR family makes it a valuable compound in targeted cancer therapy and the development of precision medicine.
Used in Research Applications:
In the research field, 3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-[6-[[4-(4-ethylpiperazin-1-yl)phenyl]amino]pyrimidin-4-yl]-1-methylurea serves as a valuable tool compound for studying the role of FGFRs in cellular processes and disease progression. It aids researchers in understanding the mechanisms of action and potential therapeutic targets within the FGFR signaling pathway.
Used in Mouse Model of Achondroplasia:
3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-[6-[[4-(4-ethylpiperazin-1-yl)phenyl]amino]pyrimidin-4-yl]-1-methylurea has been utilized in a mouse model of Achondroplasia, the most common form of dwarfism, to correct the pathological hallmarks of this condition. Its application in this context highlights its potential use in treating genetic disorders related to the FGFR family.
References
1) Guagnano?et al.?(2011),?Discovery of 3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-{[4-(4-ethyl-1-piperazinyl)phenyl]amino}-4-pyrimidinyl)-1-methylurea (NVP-BGJ398),?a Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase?; J. Med. Chem.?54?7066
2) Komla-Ebri?et al.?(2016),?Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model; J. Clin. Invest.?126?1871
Check Digit Verification of cas no
The CAS Registry Mumber 872511-34-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,2,5,1 and 1 respectively; the second part has 2 digits, 3 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 872511-34:
(8*8)+(7*7)+(6*2)+(5*5)+(4*1)+(3*1)+(2*3)+(1*4)=167
167 % 10 = 7
So 872511-34-7 is a valid CAS Registry Number.
InChI:InChI=1S/C26H31Cl2N7O3/c1-5-34-10-12-35(13-11-34)18-8-6-17(7-9-18)31-21-15-22(30-16-29-21)33(2)26(36)32-25-23(27)19(37-3)14-20(38-4)24(25)28/h6-9,14-16H,5,10-13H2,1-4H3,(H,32,36)(H,29,30,31)
872511-34-7Relevant articles and documents
CRYSTALLINE FORMS OF 3-(2,6-DICHLORO-3,5-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1-YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA AND SALTS THEREOF.
-
Page/Page column 23-24, (2011/06/26)
The present technology provides novel anhydrous and hydrated crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea, amorphous and anhydrous crystalline polymorphs of its mono